Johnson & Johnson has received a positive recommendation from the Committee for Medicinal Products for Human Use $(CHMP)$ for its drug DARZALEX® (daratumumab) as a treatment for patients with high-risk smouldering multiple myeloma. This endorsement sets the stage for potential European Commission approval, which would make daratumumab the first authorized treatment option for these patients. The recommendation is underpinned by data from the Phase 3 AQUILA study, demonstrating the drug's ability to significantly delay the onset of myeloma and extend overall survival. Johnson & Johnson has also submitted a supplemental Biologics License Application to the U.S. FDA for daratumumab's use in this new indication. If approved, it could offer a crucial new strategy for intercepting smouldering multiple myeloma before it progresses to active disease.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.